The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for exist
The fear and pessimism behind major selling pressure and stock market losses can be summarized by the late Jim Morrison in a song by The Doors called 'Roadhouse Blues' – "The future's uncertain, and the end is always near." Some stocks that I follow which are trading at less than half of the 20% decline for the S&P 500 ETF (SPY) below its 50-day moving average are highlighted below.
Earlier this week, AspenBio Pharma (APPY) reported that its key clinical trial was nearly 90% enrolled for AppyScore, which is a blood-ba
While the fate of General Motors (GM) as a company is being debated by legislators and others, investors would agree that GM will be removed from the Dow Jones Industrial Average as the common stock faces the likely prospect of heading to zero despite efforts for a bailout of workers and suppliers. Some companies to consider as a replacement for GMK include:
Abbott Labs (ABT) is a consistent performer with diversified healthcare operations included pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents
The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO),
Shares of Amgen (AMGN) have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today , Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its full-year profit guidance as it had done three months ago when reporting 2Q08 results. Even with the current pop in after-hours to around $54 per share, Amgen is only trading at a PE of 12X on the mid-point of its 2008 profit guidance of $4.45 to $4.55 per share.Amgen poste
I think Amgen (AMGN) will beat consensus estimates for sales and profits again today when it reports after the market close, continuing the same trends as last quarter, including better than expected sales of embattled anemia drugs Aranesp and Epogen. Amgen reported 2Q08 results (see conference call transcript ) that beat consensus analyst estimates and raised its full-year [FY] guidance for earnings and revenue, thanks to much stronger-than-expected sales of its anemia drugs Aranesp and Epogen:
The accompanying table presents a 20-stock defensive growth portfolio which I believe will outperform the overall market as measured by the S&P 500 Index as the current panic trade comes to an end and investors stop selling stocks regardless of their fundamentals. The average PEG ratio for this group of stocks is below one and the average dividend yield of 4.4% is nearly two times the S&P 500 ETF (SPY) yield of 2.4%. All of the stocks have a market cap over $1B with an average of just under $75B and the indust
The accompanying table presents a quarterly update of my Highly Defensive PerformIdex, with an average beta of 0.72 and a market cap-weighted total return of 7.9% over the past year, outpacing the overall market and ETF peer group -- except for Vanguard Consumer Staples (VDC) ETF with an 8% total return over this period. Two companies received buyout offers in the past three months, including Genentech (DNA) and Anheuser-Busch (BUD), which were replaced by Amgen (AMGN) and Brown-Forman (BF-B), respectively.
As previously, the market cap-weighted index consists of
Amgen (NASDAQ: AMGN) is a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and metabolic diseases. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffma
Amgen reported 2Q08 results that beat consensus analyst estimates and raised its full-year [FY] guidance for earnings and revenue, thanks to much stronger-than-expected sales of its anemia drugs Aranesp and Epogen:
2Q08 Revenue +1% at $3.8 billion [B] vs. $3.58B expected
Adjusted Earnings Per Share [EPS] of $1.14 vs. $1.02 expected
Increased EPS Guidance FY08 of $4.25 to $4.45 from $4.00 - $4.30
Increased Revenue Guidance FY08 of $14.6B - $14.9B from $14.2B - $14.6B
A surprising name has been hitting a string of new 52-week highs in the biotech space and is soaring once again today. This stock was beaten into oblivion earlier this year on fears that its growth prospects were dim and that its drug Aranesp was in trouble. However, fast forward to today and the momentum traders are catching hold of Amgen (AMGN) and bidding it higher.
The catalyst for today’s rise is positive trial data on its osteoporosis candidate denosumab. Last week, the company reported that a large-scale Phase III study showed a lower rate of vertebrate fractures among post-menopausal
Amgen Inc (AMGN) is looking very attractive heading into
earnings with the additional good news of Nplate being approved by the Food and
Drug Administration on Wednesday or Thursday.
TheStreet.com's Jim Cramer says the biotechs look sweet in a bank-led slowdown.
Thank you, New York Times. Remember just a couple of weeks ago, when The New York Times wrote about how Genentech's (NYSE: DNA) (Cramer's Take) Avastin was too expensive and the stock got cracked down to $77? I know Roche did. I bet that was the last draw. The dramatic decline in the dollar plus a sentiment that has spawn...
3/20 - "When markets get crazy you can sometimes pick up world-leading companies at extraordinary prices. I believe that type of opportunity exists right now in Amgen (AMGN)...Not only are (Amgen shares) absolutely low priced but the current P/E is just 10.4x median EPS projections for 2008...Sales and earnings are both likely to hit all-time highs this year so I see no reason for these shares to remain at such a depressed valuation."
"With consensus estimates of $4.00 for this year a return to even 17 times that number would bring Amgen shares back to $68 or up $28.00 [+70%] from today's ...
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
Take a Close Look at Amgen
- It was a relatively slow day for news coming out of the markets, and there is about as much coverage of Super Bowl commercials as anything else. Perhap...
Data powered by QuoteMedia.
All Rights Reserved.
Data delayed 15 to 20 minutes unless otherwise indicated.
Terms of Use.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you
